

Serveur Académique Lausannois **SERVAL** serval.unil.ch

Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

Title: Implementation of Enhanced Recovery (ERAS) in Colorectal Surgery Has a Positive Impact on Non-ERAS Liver Surgery Patients.

Authors: Labgaa I, Jarrar G, Joliat GR, Allemann P, Gander S, Blanc C, Hübner M, Demartines N

Journal: World journal of surgery

Year: 2016 May

Issue: 40

Volume: 5

Pages: 1082-91

DOI: 10.1007/s00268-015-3363-3

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

Original Scientific Report

Implementation of Enhanced Recovery (ERAS) in colorectal surgery has a positive impact on non-ERAS liver surgery patients.

Ismail Labgaa^{1*}, Ghada Jarrar^{1*}, Gaëtan-Romain Joliat¹, Pierre Allemann¹, Sylvain Gander², Catherine Blanc³, Martin Hübner¹ & Nicolas Demartines¹

¹ Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Switzerland

² Department of Anesthesiology, Hospital of Yverdon-les-Bains, Switzerland

³ Department of Anesthesiology, University Hospital of Lausanne (CHUV), Switzerland

* Contributed equally

Corresponding author:

Nicolas Demartines, MD

Professor and Chairman

Department of visceral surgery

University Hospital CHUV

1011 Lausanne, Switzerland

Phone: +41 21 314 24 00 / Fax: +41 21 314 24 11

E-mail: demartines@chuv.ch

Abbreviated Title (running head): ERAS –colorectal enhances non-ERAS liver surgery.

Key words: enhanced recovery, liver surgery, compliance.

Sources of financial support for the work:

Institutional financial support: Department of Visceral Surgery, University Hospital of Lausanne (CHUV), Switzerland.

All authors approved the final version.

The authors declare to have no conflicts of interests and no sources of support and funding for this work.

Presented at the *102nd Congress of Swiss Surgery*, May 2015, Bern.

Presented at the *4th World Congress of Enhanced Recovery After Surgery and Perioperative Medicine*, May 2015, Washington DC, USA.

Presented at the *101st Congress of Swiss Surgery*, May 2014, Bern.

Presented at the *116th Congress of French Surgery*, October 2014, Paris.

Number of words in: Abstract (250), Manuscript (2479)

ABSTRACT

Background

Enhanced Recovery After Surgery (ERAS) reduces complications and hospital stay in colorectal surgery. Thereafter, ERAS principles were extended to liver surgery. Previous implementation of an ERAS program in colorectal surgery may influence patients undergoing liver surgery in a non-ERAS setting, on the same ward. This study aimed to test this hypothesis.

Methods

Retrospective analysis based on prospective data of the adherence to the institutional ERAS-liver protocol (compliance) in 3 cohorts of consecutive patients undergoing elective liver surgery, between June 2010 and July 2014: before any ERAS implementation (pre-ERAS n = 50), after implementation of ERAS in colorectal (intermediate n=50), and after implementation of ERAS in liver surgery (ERAS-liver n=74). Outcomes were functional recovery, postoperative complications, hospital stay, and readmissions.

Results

The 3 groups were comparable for demographics; laparoscopy was more frequent in ERAS-liver ($p=0.009$). Compliance with the enhanced recovery protocol increased along the 3 periods (pre-ERAS, intermediate and ERAS-liver), regardless of the perioperative phase (pre-, intra- or post-operative). ERAS-liver group displayed the highest overall compliance rate with 73.8%, compared to 39.9% and 57.4% for pre-ERAS and Intermediate groups ($p=0.072/0.056$). Overall complications were unchanged ($p=0.185$), whereas Intermediate and ERAS-liver groups showed decreased major complications ($p=0.034$). Consistently, hospital stay was reduced by 2 days ($p=0.005$) without increased readmissions ($p=0.158$).

Conclusions

The previous implementation of an ERAS protocol in colorectal surgery may induce a positive impact on patients undergoing non-ERAS liver surgery on the same ward. These results suggest that ERAS is safely applicable in liver surgery, and associated with benefits.

INTRODUCTION

Enhanced recovery (ERAS) pathways have become standard of care in colorectal surgery due to significant reduction of complications, length of stay (LoS) and costs ¹⁻⁵. As a result, ERAS protocols were subsequently extended to other types of surgery, including gastric ⁶, pancreatic ⁷ and liver ⁸ surgery. The use of ERAS protocols in liver surgery appeared to be safe and feasible ⁹⁻¹¹. However, applied protocols widely varied and the assessment of their application (compliance) was rarely reported. Moreover, some ERAS protocols in liver surgery were implemented in centers having an institutional experience of ERAS in colorectal surgery. The previous implementation of ERAS in colorectal surgery presumably influence other types of surgery performed in a non-ERAS setting, provided the patients are on the same ward and treated by the same anesthetists. The usual comparative group “pre-ERAS” may thus be biased by this influence. It may be hypothesized that this impact could be observed in different protagonists: patients and medical staff. Regarding the patients, non-ERAS ones may be influenced by observing early feeding and mobilization in ERAS patients, then requesting similar care. Likewise, surgeons, anesthetists and nurses potentially modify their management of non-ERAS patients, according to ERAS principles.

The present study aimed to test this hypothesis by analyzing the compliance and the clinical outcomes of patients undergoing elective liver surgery in 3 different groups: before institutional ERAS implementation for colorectal surgery (pre-ERAS), after ERAS implementation for colorectal but before its application for liver surgery (intermediate), and after the implementation of ERAS in liver surgery (ERAS-liver).

METHODS

Enhanced recovery after surgery program (ERAS) for colorectal surgery was implemented in our institution in May 2011 in a systematic manner as recommended by ERAS Society guidelines¹². Then, ERAS was implemented in liver surgery in July 2013, by the same multidisciplinary team, in the same ward, with the same method¹³ applying an institutional formal ERAS-liver protocol. Documentation of adherence to the ERAS pathway (compliance) is key component of ERAS program, and was therefore systematically measured for all patients. Systematic comparison with patients before, during, and after implementation was performed and is detailed below. The Institutional Review Board approved the study and all patients provided written consent before surgery. The study was conducted in accordance with the STROBE criteria (<http://strobe-statement.org/>) and registered under www.researchregistry.com (UIN: 392).

Patients

The implementation of ERAS program for colorectal surgery may presumably influence perioperative care for liver resections. To test this hypothesis, 3 groups of patients were analysed: “Pre-ERAS”, “Intermediate” and “ERAS-liver”, as illustrated in **Figure 1**. Each group was a cohort of consecutive patients undergoing elective liver surgery. “Pre-ERAS” patients were included before implementation of any ERAS in colorectal surgery. “Intermediate” included patients after implementation for colorectal but before implementation of ERAS for liver resection. “ERAS-liver” included patients after implementation of the specific ERAS-liver protocol. Of note, no exclusion criteria were applied. Therefore, all consecutive patients were included, regardless of the age or any other parameter.

ERAS protocol and compliance (Table 1)

To date, no validated guidelines for enhanced recovery in liver surgery have been published by the ERAS Society. The present specific ERAS protocol for liver surgery was created by our team and adapted from the enhanced recovery pathway for colorectal surgery, published^{14,15, 16} by the ERAS Society, and from the published pancreas ERAS guidelines¹⁷. ERAS was implemented in our institution for colorectal and pancreatic surgeries in May 2011 and September 2013, respectively. Additional specific items related to liver surgery were adapted, based on available evidence. **Table 1** provides a comprehensive overview of our enhanced recovery protocol for liver surgery with the respective references. Compliance with the ERAS protocol was prospectively assessed for the different phases of perioperative care (pre-, intra- and post-operative). Briefly, enhanced recovery items were handled as dichotomous variables. Individual adherence to the protocol was calculated as percentage of compliant patients/total patients. The number of fulfilled items divided by the total number of enhanced recovery measures (%) is presented as overall compliance with the pathway.

Data collection

A dedicated trained ERAS nurse was in charge of completing the prospective database. Demographic and surgical details of all patients in the enhanced recovery pathway were captured along with detailed information on compliance with the protocol and audit of clinical outcome with a minimal follow-up of 30 postoperative days. Control of pain with oral analgesia only, stop of intravenous fluid, full mobilization and eating solid food were recorded, while postoperative complications were graded according to *Clavien classification*¹⁸ and to the Comprehensive Complication Index (CCI)¹⁹. CCI is a score that integrates and sum all postoperative complications with their respective severity, on a scale ranging from 0 (no complication) to 100 (death); underreporting of minor complications can thus be avoided and

reporting of complication is supposed to be more accurate¹⁹. Length of stay was counted from day of surgery until discharge. Discharge was decided on pre-established criteria: control of pain with oral analgesia, eating solid food, return of bowel function, full mobilization.

Readmissions were considered within 30 days after surgery.

Statistics

Descriptive statistics for categorical variables were reported as frequency (%), while continuous variables were reported as median (interquartile range). Continuous variables were compared between “pre-ERAS”, “Intermediate” and “ERAS-liver” groups with the Kruskal Wallis test. Chi-square was used for comparison of categorical variables. All statistical tests were two-sided and a level of 0.05 was used to indicate statistical significance. Data analyses were performed using SPSS v20 statistical software, Chicago, IL.

RESULTS

Patients

Seventy-four patients who underwent liver surgery in the “ERAS-liver” group were compared to 50 patients in the “pre-ERAS” group, and 50 patients in the “intermediate” group. Baseline demographics were similar between the 3 groups (**Table 2**). Patients in the ERAS-liver group had more laparoscopic procedures than the comparative groups (4.1% vs. 14% vs. 24.7%) ($p=0.009$), and less pedicular clamping (68%, 28%, 39.2%, $p<0.001$). The characteristics of surgery are detailed in **table 3**.

ERAS implementation and compliance with the protocol

Compliance with the enhanced recovery pathway steadily increased along the 3 periods (pre-ERAS, intermediate and ERAS-liver), regardless of the perioperative phase (pre-, Intra- or post-operative). While intra-operative phase globally displayed the highest compliance rate, pre-

operative and postoperative items were the most influenced by the implementation of an ERAS pathway (**Figure 2**).

Figure 3 illustrates each ERAS items displaying a significant difference across the groups, in term of compliance rate (all ERAS items are detailed in **Appendix 1**). Regarding preoperative phase, ERAS-liver group displayed greater compliance rate for each item, with a mean rate of 81.1%, comparing to 32.2% and 4.5% in intermediate and pre-ERAS groups, respectively ($P < 0.001$). A significant difference was highlighted in 3 intraoperative items: avoidance of nasogastric tube ($p < 0.001$), PONV prophylaxis ($p < 0.001$) and the use of pneumatic boots ($p < 0.001$). ERAS implementation showed a significant impact on postoperative phase, with most items showing statistical differences between the studied groups: balanced IV fluid at POD 0 ($p < 0.001$), start of intake water and free fluids at POD 0 ($p < 0.001$), mobilization at POD 0 ($p = 0.04$), oral analgesia at POD 1 ($p < 0.001$), normal diet at POD 1 ($p < 0.001$), full mobilization at POD1 ($p = 0.015$), UC removal at POD 3 ($p = 0.019$) and stop epidural/intravenous analgesia at POD4 ($p = 0.001$).

Functional recovery (Figure 4)

The duration of intravenous or subcutaneous analgesia in liver patients was reduced after both implementations of ERAS in colorectal ($p = 0.001$) and liver surgery ($p < 0.001$). Discontinuation of intravenous fluid ($p = 0.016$) and full mobilization ($p = 0.023$) were mostly influenced by the institutional implementation of ERAS for colorectal surgery. Regarding intake of solid food, the 3 compared groups did not display any difference ($p = 0.093$). Likewise, the postoperative normalization of serum bilirubin remained comparable across the groups ($p = 0.137$) (data not shown).

Complications, length of stay (Table 4)

Overall postoperative morbidity did not differ between the comparative groups and is summarized in detail in **Table 4**. However, intermediate and ERAS-liver groups showed a significant reduction of major complications in comparison to pre-ERAS group (10% and 13.5% vs 28%, respectively; $p=0.034$). Consistently, hospital stay was significantly reduced by about two days in intermediate and ERAS-liver groups (10.5, 8.5, 8 days, $p=0.005$), without increasing readmission rate (2%, 12%, 8.1%, $p=0.158$). Furthermore, introduction of ERAS permitted shorter stays within Intensive Care (3 vs. 2 vs. 2 nights, $p=0.001$) and Intermediate Care Units (1 vs. 0 vs. 0 night) ($p<0.001$) with similar admission and discharge criteria.

DISCUSSION

To the best of our knowledge, the collateral impact of an ERAS program implementation on a non-ERAS specialty within the same department – supported by a thorough assessment of the compliance-may have been suspected, but was measured for the first time herein. The present findings suggest that the previous implementation of an ERAS pathway in colorectal surgery had a positive collateral impact on patients undergoing liver surgery in a non-ERAS program. In addition, the present results also confirm that ERAS pathway is applicable and associated with benefits, in liver surgery.

After the successful implementation of ERAS in colorectal surgery, some enhanced recovery items were “unconsciously” introduced and applied in patients undergoing liver surgery in a non-ERAS setting. After the systematic application of a specific liver protocol, compliance was further increased along with improvements of both functional and clinical outcomes. Liver metastases from colorectal cancer represent an important indication for liver resection in the present series. However, the majority of patients with synchronous colorectal liver metastasis underwent “liver first” approach²⁰, whereas most patients referred from other centers

experienced surgery for the primary colorectal tumor, in a non-ERAS setting. As a result, only 9 patients (12%) of the group ERAS-Liver were previously operated in a formal ERAS-colorectal setting. This limited subset of patients is unlikely to be the only cause of the increased compliance observed after ERAS implementation.

Strikingly, the results of this study give rise to two major concepts: (I) the landscape of the benefits associated with the implementation of ERAS in colorectal surgery is redrawn and (II) the role of randomized trials addressing the effect of ERAS may be questioned. Regarding the former, it was already established that the implementation of ERAS in colorectal surgery had a positive impact on patients with reduced complications and LoS¹⁻⁵. In addition, ERAS in colorectal surgery was also proven to be cost-effective¹³. Importantly, this present study demonstrates a broader interest of implementing ERAS in colorectal surgery, since it seems to also positively influence patients undergoing other types of surgery, provided they are located on the same ward. Therefore, the present findings are challenging the role of prospective clinical studies to address to effect of ERAS, since the control group (non-ERAS) is at risk to be biased by the previous institutional implementation of ERAS, like the intermediate group in the present study. Blind trials comparing enhanced recovery and traditional care are not a realistic option (drain vs. no drain, bed rest vs. early mobilization or, early feeding vs. traditional postoperative fasting until bowel recovery, etc.). So either prospective randomized study should be conducted in different hospitals and different teams, or enhance recovery programs should be compared with historical cohorts; both designs display intrinsic limitations.

Monitoring compliance is particularly crucial in enhanced recovery program since it determines whether the protocol is actually applied^{21, 22}. Comparison with other published studies is somehow awkward for two reasons: high heterogeneity of protocols, and rarely reported compliance with the applied protocol. As a consequence, some negative reported results on

recovery programs may presumably be due to a low compliance with the protocol rather than to a failure of the recovery protocol itself.

Furthermore, as no validated ERAS protocol has been published yet for liver surgery, a variety of heterogeneous ERAS-liver protocols has been applied and published²³. In comparison with other published protocols, the present one was stricter for food intake (normal diet at POD 1) and mobilization (full mobilization at POD 1). Conversely, it was more conservative for urinary catheter removal (POD 3, instead of POD 1-2)^{11, 23, 24}. Most reported studies were designed to analyse outcomes, rather than compliance^{9, 10, 25}. Of note, the compliance rate measured in this present study was higher than in other studies^{23, 26}. As an example, the avoidance of nasogastric tube and abdominal drain was achieved in 97.3% and 54.1% respectively, while a recently published multicentric study reported 53% and 41%, respectively²³.

Comparable to compliance, functional recovery substantially differed between studies. Although several studies supported the positive impact of enhanced recovery pathway on recovery, they did not thoroughly analyse functional recovery following liver surgery^{8, 9, 24}. In this regard, the present results showed an improvement of pain control, duration of intravenous fluid and full mobilization, after liver ERAS implementation. Consistently with previous reports, a reduced length of stay without any increasing in readmission rate was observed⁸⁻¹⁰. It may be hypothesized that this effect is due to the enhanced recovery protocol itself, or to the systematisation of perioperative management based on clinical pathway; this is however beyond the scope of the present study and deserves further investigations.

Regarding shorter length of stay^{8, 10, 27, 28}, this reduction could result from reduced complications. However, comparing LoS between different countries with different healthcare systems is often biased, the most important factor being the reduction in LoS after the introduction of a recovery program, rather than its absolute value.

The analysis of the overall morbidity –using the Comprehensive Complication Index (CCI) – showed a median value of 8.7 in ERAS-Liver, while CCI reached 20.9 for both pre-ERAS and intermediate groups, which was however not significant ($p=0.185$).

With a design including 3 comparative groups along ERAS implementation, this present study was able to measure the unique aspect of an intermediate group after ERAS colorectal but before ERAS liver.

Several limitations of the present study have to be addressed. Although the 3 compared groups were similar for most studied variables, ERAS group displayed higher rate of laparoscopic procedures ($p=0.009$) and less inflow clamping ($p<0.001$). This probably reflects the current evolution of liver surgery, with the extension of non-invasive techniques. This difference may partially explain the better outcome observed in ERAS-liver, notably the reduced LoS. Although, laparoscopic surgery was increasingly performed over time, its indication was limited to left lateral sectionectomy or anterior wedge resection, thus minimizing its effect on the overall LoS. A potential bias effect can however not be completely excluded²⁵. Of note, *Stoot et al.* have showed that enhanced recovery pathway may also be beneficial in laparoscopic liver surgery; laparoscopy may thus be regarded as a constitutive item of enhance recovery. In addition - although the data were collected in a prospective database- its retrospective analysis is associated with intrinsic limitations.

In conclusion, the present study suggests that the implementation of an ERAS protocol for colorectal surgery induces a positive collateral impact on non-ERAS liver surgery patients, provided they are located on the same ward and treated by the same team. Moreover, these results confirm that ERAS-liver pathway is applicable and beneficial in liver surgery with significantly enhanced functional recovery and reduced LoS, without impairing morbidity or readmission.

Acknowledgements

The authors would like to acknowledge the support provided by all members of the enhanced recovery team in Lausanne, and especially the dedicated surgical nursing team with their leaders V. Addor, N. Zehnder, A. Jannot. A particular attention is paid to the outstanding efforts and contribution achieved by V. Addor for the data management.

Statement of Authorship

Ismail Labgaa: conception and design, analysis, interpretation and writing

Ghada Jarrar: collection of data and interpretation

Gaetan-Romain Joliat: conception and design, interpretation and critical revision

Pierre Allemann: conception and design, interpretation and critical revision

Sylvain Gander: conception and design, interpretation and critical revision

Catherine Blanc: collection of data, interpretation and critical revision

Martin Hübner: conception and design, interpretation, drafting and critical revision

Nicolas Demartines: conception and design, interpretation and major editing

All authors approved the final version.

The authors declare to have no conflicts of interests and no sources of support and funding for this work.

REFERENCES

1. Rawlinson A, Kang P, Evans J, *et al.* A systematic review of enhanced recovery protocols in colorectal surgery *Ann R Coll Surg Engl* 2011; 93; 583-588
2. Wind J, Polle SW, Fung Kon Jin PH, *et al.* Systematic review of enhanced recovery programmes in colonic surgery *Br J Surg* 2006; 93; 800-809
3. Varadhan KK, Neal KR, Dejong CH, *et al.* The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials *Clin Nutr* 2010; 29; 434-440
4. Kehlet H Surgery: Fast-track colonic surgery and the 'knowing-doing' gap *Nat Rev Gastroenterol Hepatol* 2011; 8; 539-540
5. Spanjersberg WR, Reurings J, Keus F, *et al.* Fast track surgery versus conventional recovery strategies for colorectal surgery *Cochrane Database Syst Rev* 2011; CD007635
6. Findlay JM, Gillies RS, Millo J, *et al.* Enhanced recovery for esophagectomy: a systematic review and evidence-based guidelines *Ann Surg* 2014; 259; 413-431
7. Hall TC, Dennison AR, Bilku DK, *et al.* Enhanced recovery programmes in hepatobiliary and pancreatic surgery: a systematic review *Ann R Coll Surg Engl* 2012; 94; 318-326
8. van Dam RM, Hendry PO, Coolen MM, *et al.* Initial experience with a multimodal enhanced recovery programme in patients undergoing liver resection *Br J Surg* 2008; 95; 969-975
9. Hughes MJ, McNally S, Wigmore SJ Enhanced recovery following liver surgery: a systematic review and meta-analysis *HPB (Oxford)* 2014; 16; 699-706
10. Jones C, Kelliher L, Dickinson M, *et al.* Randomized clinical trial on enhanced recovery versus standard care following open liver resection *Br J Surg* 2013; 100; 1015-1024

11. Coolsen MM, Wong-Lun-Hing EM, van Dam RM, *et al.* A systematic review of outcomes in patients undergoing liver surgery in an enhanced recovery after surgery pathways HPB (Oxford) 2013: 15; 245-251
12. Lassen K, Soop M, Nygren J, *et al.* Consensus review of optimal perioperative care in colorectal surgery: Enhanced Recovery After Surgery (ERAS) Group recommendations Arch Surg 2009: 144; 961-969
13. Roulin D, Donadini A, Gander S, *et al.* Cost-effectiveness of the implementation of an enhanced recovery protocol for colorectal surgery Br J Surg 2013: 100; 1108-1114
14. Roulin D, Blanc C, Muradbegovic M, *et al.* Enhanced recovery pathway for urgent colectomy World J Surg 2014: 38; 2153-2159
15. Gustafsson UO, Scott MJ, Schwenk W, *et al.* Guidelines for perioperative care in elective colonic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations World J Surg 2013: 37; 259-284
16. Nygren J, Thacker J, Carli F, *et al.* Guidelines for perioperative care in elective rectal/pelvic surgery: Enhanced Recovery After Surgery (ERAS((R))) Society recommendations World J Surg 2013: 37; 285-305
17. Lassen K, Coolsen MM, Slim K, *et al.* Guidelines for perioperative care for pancreaticoduodenectomy: Enhanced Recovery After Surgery (ERAS(R)) Society recommendations Clin Nutr 2012: 31; 817-830
18. Dindo D, Demartines N, Clavien PA Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey Ann Surg 2004: 240; 205-213
19. Slankamenac K, Graf R, Barkun J, *et al.* The comprehensive complication index: a novel continuous scale to measure surgical morbidity Ann Surg 2013: 258; 1-7

20. Mentha G, Majno PE, Andres A, *et al.* Neoadjuvant chemotherapy and resection of advanced synchronous liver metastases before treatment of the colorectal primary Br J Surg 2006: 93; 872-878
21. Gustafsson UO, Hausel J, Thorell A, *et al.* Adherence to the enhanced recovery after surgery protocol and outcomes after colorectal cancer surgery Arch Surg 2011: 146; 571-577
22. Maessen J, Dejong CH, Hausel J, *et al.* A protocol is not enough to implement an enhanced recovery programme for colorectal resection Br J Surg 2007: 94; 224-231
23. Wong-Lun-Hing EM, van Dam RM, Heijnen LA, *et al.* Is current perioperative practice in hepatic surgery based on enhanced recovery after surgery (ERAS) principles? World J Surg 2014: 38; 1127-1140
24. Connor S, Cross A, Sakowska M, *et al.* Effects of introducing an enhanced recovery after surgery programme for patients undergoing open hepatic resection HPB (Oxford) 2013: 15; 294-301
25. Stoot JH, van Dam RM, Busch OR, *et al.* The effect of a multimodal fast-track programme on outcomes in laparoscopic liver surgery: a multicentre pilot study HPB (Oxford) 2009: 11; 140-144
26. Hammond JS, Humphries S, Simson N, *et al.* Adherence to enhanced recovery after surgery protocols across a high-volume gastrointestinal surgical service Dig Surg 2014: 31; 117-122
27. Dasari BV, Rahman R, Khan S, *et al.* Safety and feasibility of an enhanced recovery pathway after a liver resection: prospective cohort study HPB (Oxford) 2015
28. Schultz NA, Larsen PN, Klarskov B, *et al.* Evaluation of a fast-track programme for patients undergoing liver resection Br J Surg 2013: 100; 138-143

29. Smith I, Kranke P, Murat I, *et al.* Perioperative fasting in adults and children: guidelines from the European Society of Anaesthesiology *Eur J Anaesthesiol* 2011; 28; 556-569
30. Cerantola Y, Hubner M, Grass F, *et al.* Immunonutrition in gastrointestinal surgery *Br J Surg* 2011; 98; 37-48
31. Hill J, Treasure T, Guideline Development G Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in patients admitted to hospital: summary of the NICE guideline *Heart* 2010; 96; 879-882
32. Song F, Glenny AM Antimicrobial prophylaxis in colorectal surgery: a systematic review of randomized controlled trials *Br J Surg* 1998; 85; 1232-1241
33. Kranke P, Eberhart LH Possibilities and limitations in the pharmacological management of postoperative nausea and vomiting *Eur J Anaesthesiol* 2011; 28; 758-765
34. Giglio MT, Marucci M, Testini M, *et al.* Goal-directed haemodynamic therapy and gastrointestinal complications in major surgery: a meta-analysis of randomized controlled trials *Br J Anaesth* 2009; 103; 637-646
35. Brooke-Smith M, Figueras J, Ullah S, *et al.* Prospective evaluation of the International Study Group for Liver Surgery definition of bile leak after a liver resection and the role of routine operative drainage: an international multicentre study *HPB (Oxford)* 2015; 17; 46-51
36. Nelson R, Edwards S, Tse B Prophylactic nasogastric decompression after abdominal surgery *Cochrane Database Syst Rev* 2007; CD004929
37. Convertino VA Cardiovascular consequences of bed rest: effect on maximal oxygen uptake *Med Sci Sports Exerc* 1997; 29; 191-196

Table 1: The institutional enhanced recovery pathway for colorectal and liver surgery

Item	Colorectal	Liver	Ref
Pre-operative items			
Preoperative counselling	Preadmission counseling and written information	Same	15
Bowel preparation	Avoidance of bowel preparation	Not relevant	
Fasting	Clear fluids until 2h before surgery, solids 6h before surgery	Same	29
Carbohydrate drinks	800 ml the evening before surgery and 400 ml 2h before surgery	Same	16
Immunonutrition (IN)	IN could be considered in open colonic resections	Same	30
Premedication	No pre-operative long-acting sedative premedication	Same	16
Thromboprophylaxis	LMW heparin 12h before surgery, IPC	Same	31
Intra-operative items			
Antibiotic prophylaxis	Cefuroxime 1.5g+metronidazole 500, 30min before incision	Cefuroxime 1.5g, 30min before incision	32
Hypothermia prevention	Active warming with air blanket	Same	
PONV prophylaxis	Droperidol 1mg at induction, ondansetron 4 mg ± betamethasone 4mg at the end of surgery	Same	33
Post-operative items			
Balanced IV fluids	Intraoperative cristalloid quantity depending on the operation avoiding salt and water overload. Postoperative cristalloids 1000 ml for the first 24h then 500 ml/24h for the first postoperative days	Goal directed fluid therapy with low CVP during liver resection, restoration of euolemia after the resection.	34
Postoperative analgesia	Epidural or PCA removed after 48h. Paracetamol, ibuprofen, and oxycodone-Naloxone only for breakthrough pain	Paracetamol, metamizole, Epidural removed on POD 4 and switch to oral opioids	15
Abdominal drains	No routine abdominal drainage	Same	35
Nasogastric tube	No routine postoperative use	Same	36
Urinary catheter	Removal on POD 1	Removal on POD 3	16
Nutrition	Free fluids 4h after surgery. Normal diet from day of surgery. Two nutritional supplements (300 kcal/unit) per day.	Free fluids 4h after surgery. Normal diet on POD 1. Two Nutritional supplements per day	16
Laxatives	Oral magnesium hydroxide ± chewing gum	Same	
Mobilization	Out of bed more than 15 min on day of surgery, at least 6h per day thereafter.	Same	37
Systematic audit	Systematic audit, meeting every 2 weeks.	Ongoing implementation	21

LMW: low molecular weight, IPC: intermittent pneumatic compression, PONV: postoperative nausea and vomiting, PCA: patient-controlled analgesia, POD: postoperative day.

^a Betamethasone only for women or non-smokers or those with previous history of PONV.

Table 2: Patients' characteristics

	Pre-ERAS (n=50)	Intermediate (n=50)	ERAS-liver (n=74)	P value
Age (years) *	64 (59-69)	64 (57-73)	60 (49.75-68)	0.073
Sex ratio, (M:F)	35:15	25:25	43:31	0.122
Body mass index (kg/m ²) *	24.8 (23.3-27.8)	24.5 (21.4-27.5)	25.3 (21.6-29)	0.749
ASA grade §				0.77
I-II, n (%)	36 (72%)	35 (70%)	56 (75.7%)	
III-IV, n (%)	14 (28%)	15 (30%)	18 (24.3%)	
Cirrhosis n, (%) §	6 (12%)	6 (12%)	4 (5.4%)	0.33
Smoker n, (%) §	9 (18%)	10 (20%)	16 (21.6%)	0.885
Diabetes n, (%) §	13 (26%)	6 (12%)	13 (17.6%)	0.19
Diagnosis §				0.425
Neoplasia, n (%)	43 (86%)	44 (88%)	55 (74.3%)	0.099
HCC, n (%)	6 (12%)	10 (20%)	10 (13.5%)	
Cholangiocarcinoma, n (%)	2 (4%)	7 (14%)	9 (12.2%)	
Metastasis, n (%)	25 (50%)	21 (42%)	31 (41.9%)	
Echinococcosis, n (%)	5 (10%)	2 (4%)	11 (14.9%)	
Benign lesions	2 (4%)	3 (6%)	5 (6.8%)	
Others	10 (20%)	7 (14%)	8 (10.8%)	

Values are median (IQR). § Chi-square test, * Kruskal Wallis

ASA, American Society of Anesthesiologists. HCC: Hepatocellular Carcinoma. Additional procedure: cholecystectomy was not included. Major resection: ≥3 resected segments. Minor resection: <3 resected segments.

Table 3: Types of surgery

	Pre-ERAS (n=50)	Intermediate (n=50)	ERAS-Liver (n=74)	P value
Surgical approach §				0.009
Laparoscopic, n (%)	2 (4.1%)	7 (14%)	18 (24.7%)	
Open, n (%)	47 (95.9%)	43 (86%)	55 (75.3%)	
Procedure §				0.914
Major resection, n (%)	22 (44%)	21 (42%)	30 (41.1%)	
Minor resection, n (%)	27 (54%)	29 (58%)	43 (58.9%)	
Anastomosis, n (%)	4 (8.2%)	5 (10%)	11 (14.9%)	0.481
Clamping, n (%)	34 (68%)	14 (28%)	29 (39.2%)	<0.001

Values are median (IQR). § Chi-square test, * Kruskal Wallis
 ASA, American Society of Anesthesiologists. HCC: Hepatocellular Carcinoma. Additional procedure:
 cholecystectomy was not included. Major resection: ≥3 resected segments. Minor resection: <3 resected
 segments.

Table 4: Complications and hospital stay

	Pre-ERAS (n=50)	Intermediate (n=50)	ERAS-Liver (n=74)	P value
30d complications (No. of patients, %) [§]				
overall	30 (60%)	33 (66%)	37 (50.7%)	0.224
I-II, n (%)	25 (50%)	31 (62%)	36 (48.6%)	0.306
III-IV, n (%)	14 (28%)	5 (10%)	10 (13.5%)	0.034
V, n (%)	0 (-)	2 (4%)	1 (1.4 %)	0.291
CCI *	20.9 (0-31.5)	20.9 (0-25.6)	8.7 (0-21.3)	0.185
Hospital stay (days)*	10.5 (8-17)	8.5 (6.75-14.25)	8 (6-11)	0.005
Nights in ICU *	3 (2-5)	2 (1-4)	2 (1-3.25)	0.001
Nights in IC *	1 (0-2)	0 (0-1)	0	<0.001
30d re-admissions, n (%)[§]	1 (2%)	6 (12%)	6 (8.1%)	0.158

Values are median (IQR), [§]Chi-square test, *Kruskal Wallis.

POD: Postoperative day. CCI: Comprehensive Complications Index. ICU: Intensive Care Unit. IC: Intermediate Care.

Figure 1: Comparative groups and time frame




Figure 2: Compliance with the ERAS pathway over time




Figure 3: ERAS items with significantly different compliance rate across the groups






Figure 4: Functional recovery



Appendix I: Compliance rate of each ERAS items for the three comparative groups



The bars indicate the percentage of patients who adhered to the individual measures of the ERAS protocol. Results are presented for the three comparative groups "pre-ERAS" (green), "intermediate" (red) and ERAS-liver (blue).

* indicates statistical significance: $P < 0.05$.